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Abstract: Pharmaceutical crops is an ambiguous term used by biologists and chemists for different categories of plants.
This review focuses on the definition and scope of pharmaceutical crops. We define pharmaceutical crops as those cultivated species that are used for extraction or preparation of therapeutic substances such as active pharmaceutical ingredients (APIs), excipients used in pharmaceutical formulations, vaccines and antibodies, as well as other therapeutic proteins.
Based on the type of pharmaceutical product, these crops can be classified into three distinct yet sometimes overlapping
categories: crops for the production of small therapeutic molecules (STMs), large therapeutic molecules (LTMs), or standardized therapeutic extracts (STEs). This review briefly discusses the relationships of pharmaceutical crops with traditional food crops, medicinal plants, medicinal crops, and invasive species. It also addresses the importance, advantages,
problems, and challenges of research and development of pharmaceutical crops.

Keywords: Pharmaceutical crops, definition, active pharmaceutical ingredients, small therapeutic molecules, large therapeutic
molecules, standardized therapeutic extracts, medicinal plants, medicinal crops.
WHAT ARE PHARMACEUTICAL CROPS?
Pharmaceutical crops is an ambiguous term used by scientists of varying disciplines referring to different categories
of plants and their utilization. Biologists often define pharmaceutical crops as genetically modified (GM) or engineered crops to produce vaccines, antibodies, and other
therapeutic proteins [1-4], but sometimes, other terms for
such a class of crops or practice are used. For example,
pharma crops is used to designate transgenic plants for the
production of pharmaceuticals (e.g., antibiotics, diagnostic
compounds, antibodies, vaccines, etc.) or industrially-useful
biomolecules (e.g., biodegradable plastics, engine oils, food
processing enzymes, etc.), rather than for the production of
food, feed or textile fibers [1]. Biopharming means a practice
of using GM or engineered crops (e.g., tobacco, maize, soybeans, tomato, rice, wheat, potato, safflower, alfalfa, and leaf
mustard) as bioreactors to produce large therapeutic molecules [5]. However, natural product chemists occasionally
use the term pharmaceutical crops for a different class of
plants, those that produce pure small molecules as active
*Address correspondence to this author at the National Center for Pharmaceutical Crops, Arthur Temple College of Forestry and Agriculture, Stephen
F. Austin State University, Nacogdoches, TX 75972, USA; Tel: 936-4682071, 936-468-5600; Fax: 936-468-7058; E-mail: lis@sfasu.edu
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pharmaceutical ingredients, although there is not any clear
definition [6, 7]. These pharmaceutical ingredients are naturally-occurring single entities of secondary metabolites in
plants. Well known examples for this chemical definition are
Taxus spp. (Taxaceae) and Podophyllum spp. (Berberidaceae) for production of anti-cancer drugs, and Artemisia
annua L. (Asteraceae) for an anti-malarial drug. The different meanings of pharmaceutical crops as used by biologists
and chemists may not only cause confusion in academia and
industry, but also may often mislead the public.
We define the term Pharmaceutical Crops as those cultivated species that are used for the extraction or preparation
of therapeutic substances such as active pharmaceutical ingredients (APIs), excipients used in pharmaceutical formulations, vaccines and antibodies, as well as other therapeutic
proteins. Based on the type of pharmaceutical product, these
crops can be classified into three distinct yet sometimes
overlapping categories: crops for the production of small
therapeutic molecules (STMs), large therapeutic molecules
(LTMs), and standardized therapeutic extracts (STEs) (Table
1). Pharmaceutical crops can be either terrestrial or aquatic
species. Although marine organisms have shown promising
potential in drug discovery [8-10], this review focuses on
examples of terrestrial plants as pharmaceutical crops. It is
estimated that there are 400-500 plant species currently man2010 Bentham Open
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Summary of Three Types of Pharmaceutical Crops
Pharmaceutical Crops for the Production of
Small Therapeutic Molecules
(STMs)

Therapeutic Substances
Molecule Type
Molecular Weight

Basically secondary metabolites
Low molecular weight (usually <1,000)

Molecular Origin
Purity
In vitro Production

Endogenous
Pure
Possible but most are not commercially
feasible yet
Possible and relatively easy
Relatively easy

Biotransformation
Quality Control
Crops
Type

Traditional (possible Transgenic in the
future)
< 100 yrs

Cultivation History
Induction
Ethnobotanic Uses

Possible by stresses
Many are used in traditional medicines

aged as pharmaceutical crops for production of STMs, fewer
species are used for production of LTMs, and thousands of
species are managed as crops for STEs.
Pharmaceutical Crops for the Production of Small
Therapeutic Molecules (STMs)
This group of pharmaceutical crops produces STMs
(usually having a molecular weight of less than 1,000
Daltons) as either APIs or their precursors. Typically, these
small molecules are secondary metabolites. The plants producing these STMs are often managed as new or potential
crops via intact plant systems, tissue or cell culture systems.
Some crops in this category are well known for the production of promising active ingredients which are used directly or semi-synthetically modified as anti-cancer drugs. In
the late 1960s, Dr. Monroe Wall, Dr. Mansukh Wani, and
colleagues at the Research Triangle Institute isolated and
characterized the anti-tumor pentacyclic alkaloid camptothecin (CPT) (1) (Fig. 1) from the wood and bark of Camptotheca acuminata Decne. (Cornaceae) [11]. Because CPT
(1) is insoluble in water, its water-soluble sodium salt was
used in the initial clinical trials of the 1970s, but the results
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Fig. (1). Camptothecin (1) and 10-hydroxycamptothecin (2), two
natural alkaloids isolated from Camptotheca spp. and their semisynthetic anti-cancer drugs topotecan (3) and irinotecan (4) (Camptotheca acuminata cultivated in Texas, USA, photo by S.Y. Li).

Large Therapeutic Molecules
(LTMs)

Standardized Therapeutic Extracts
(STEs)

Basically primary metabolites
High molecular weight (usually
10,000 to 100,000)
Endogenous or exogenous
Pure
Possible but most are not commercially feasible yet
No data
Relatively easy

Both
Usually of low molecular weight

Traditional or Transgenic

Traditional

Non-transgenic crops: <100 yrs
Transgenic crops: <20 yrs
No data
Transgenic crops are not used in
traditional medicines

Many cultivated for centuries

Endogenous
Mixture
May be unable to produce the same
quality products
No data
Relatively difficult

Difficult to manage
Usually used in traditional medicines

were not promising [12]. Interest in CPT drugs was not rekindled until its unique mechanism of action was discovered.
In 1985, Hsiang et al. found that CPT traps the enzyme
topoisomerase I (TOPI), in complex with DNA, thus preventing cancer cell DNA replication and killing tumor cells
[13]. From 1985 to 1995, extensive research efforts were
focused on developing water-soluble and bioactive analogs
of natural CPT (1) and 10-hydroxycamptothecin (HCPT) (2)
(Fig. 1). In the mid-1990s, two CPT analogs, topotecan (Hycamtin®) (3) (Fig. 1) and irinotecan (trade names Camptosar® and Campto, also known as CPT-11) (4) (Fig. 1), received the United States Food and Drug Administration
(FDA) approvals and have been primarily used in patients
with advanced ovarian and metastatic colorectal cancers,
respectively. In the last decade, the global annual sales of the
two CPT drugs totaled approximately $1 billion. The semisynthetic production of these two CPT drugs and several
other CPT analogs for clinical trials requires CPT (1) or
HCPT (2) as precursors.
Camptotheca species (known by various common names
including happytree, tree of life, cancer tree in English and xi
shu in Chinese) are still a major source of CPT (1) and
HCPT (2). The genus currently includes three species of deciduous trees (C. acuminata, C. lowreyana S. Y. Li, and C.
yunnanensis Dode) and its range is restricted to remote areas
in southern China [14]. No wild trees of C. acuminata were
identified in a 1994-1997 national survey of that nation, although this species is commonly cultivated as an urban street
tree in southern China. In 1997, it was listed as an endangered species in China. Currently, fruits or leaves are harvested from cultivated C. acuminata trees along roads or
small plantations for CPT (1) and HCPT (2) extraction.
Camptotheca lowreyana and C. yunnanensis have small wild
populations with tens of mature trees only in Guangdong and
Yunnan provinces. Four high CPT-yielding cultivars of
shrubs or trees were developed to harvest leaves and stems
for sustainable production of CPTs: C. lowreyana ‘Katie’,
‘CT168’, and ‘Hicksii’, and C. yunnanensis ‘Tropic’ [14,
15]. A cultivation technique to enhance biosynthesis of CPTs
in Camptotheca was developed [16].
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Taxus L. (yew) is another example of an important pharmaceutical crop utilized for anti-cancer drug production. In
the early 1970s, Wall, Wani, and co-workers isolated and
elucidated the structure of the terpene paclitaxel (Taxol®) (5)
(Fig. 2) from the bark of Pacific yew (Taxus brevifolia Peattie) (Fig. 2), an evergreen and coniferous tree of the Taxaceae from the old-growth forests of the North American
Pacific Northwest [17, 18]. The Pacific yew was long considered a “trash tree” [18]. Susan Horwitz demonstrated that
paclitaxel’s unique antimitotic mechanism of action is to
promote microtubule assembly and inhibit mitosis rather
than preventing the formation of microtubules as with previous anti-cancer drugs [19, 20]. The unique structure and
mode of action stimulated global interest in the drug’s development. In the last two decades, paclitaxel (with various
trade names including Taxol®, Onxal, Onxol®, Abraxane®,
Apo-Paclitaxel®, Asotax, Bristaxol, Cryoxet, and Praxel) has
been one of the most widely used chemotherapy agents in
the world, particularly in patients with advanced and metastatic ovarian and breast cancers. Docetaxel (Taxotere®) (6)
(Fig. 2), a semi-synthetic analog is mainly used to treat nonsmall cell lung cancer. Ortataxel (7) (Fig. 2), a third generation taxane is now in Phase II clinical trials against taxaneresistant breast cancer [21].
The early production of paclitaxel (5) relied on the bark
of Pacific yew, with a limited supply of this nonrenewable
source. The yield of paclitaxel (5) from the yew bark is tremendously low; with 3,000 yew trees being needed to harvest enough bark to produce 1 kg of paclitaxel (5). Currently,
paclitaxel (5), docetaxel (6), and ortataxel (7) can be produced by semi-synthesis using 10-deacetylbaccatin III (10DAB) (8) (Fig. 2) and other baccatins isolated from needles
of European yew (T. baccata L.) and other yew species [22,
23]. Over 400 taxanes have been isolated from various species of Taxus [24]. Species cultivated for production of pacliO
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Two other well-known pharmaceutical crops cultivated
for anti-cancer drug production are Podophyllum L.
(mayapple) and Catharanthus roseus (L.) G. Don
(Madagascar periwinkle or rosy periwinkle). Podophyllum is
a genus of six species of herbaceous perennial plants native
to eastern Asia (five species) and eastern North America
(one species). Eastern Asian P. emodi Wall. (syn. P. hexansdrum Royle) and North American P. peltatum L. (Fig. 3)
have long been used in traditional medicine. Toxic podophyllin (a resin) from an ethanol extract of the rhizomes has
been used to treat warts. In 1880, podophyllotoxin (9) (Fig.
3), an aryltetrainlactone cyclolignan, was isolated from P.
peltatum rhizomes [24]. Etoposide (10) (Fig. 3) and
teniposide (11) (Fig. 3), two semi-synthetic analogs of podophyllotoxin (9), are potent DNA TOPII cancer drugs used for
small cell lung and testicular cancers and lymphomas/leukemias; likewise the water-soluble etoposide phosphate (also known as etopophos) (12) is used for refractory
testicular cancer and small cell lung cancer (Fig. 3). At present, both P. emodi and P. peltatum are cultivated for isolation of podophyllotoxin (9) [26, 27]. Catharanthus roseus
(also known as Vinca rosea L., family Apocynaceae) (Fig. 4)
is an evergreen perennial species native and endemic to
Madagascar, but now naturalized throughout the tropics and
widely sold as a cultivated plant elsewhere. It is used for
production of vinblastine (13) and vincristine (14) (Fig. 4),
two well-known antimitotic cancer drugs used to treat Hodgkin’s lymphoma and acute childhood lymphoblastic leukemia, respectively. Vinorelbine (Navelbine®) (15) and
vindesine (Eldisine®) (16) (Fig. 4), two synthetic drugs derived from vinca alkaloids, are used to treat non-small cell
lung and advanced breast cancers, acute lymphoblastic leukemia, and malignant melanoma [24].
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taxel (5) since the 1990s include T. brevifolia in North
America, T. baccata in Europe, T. wallichiana Zucc. (syn. T.
yunnanensis W. C. Cheng & L. K. Fu), T. cuspidata Sieb. &
Zucc. in China, and T. canadensis Marshall in Canada. In
China, for example, 6672 hectares of Taxus plantations, including the species T. madia (T. cuspidata × T. baccata), T.
wallichiana, T. wallichiana var. chinensis (Pilger) Florin,
and T. cuspidata, were located in 19 provinces in May 2005
[25]. Although numerous companies supply Taxus seedlings,
a high-yielding, fast growing cultivar is not yet available [25].
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Fig. (2). Anti-cancer taxane drugs paclitaxel (5), docetaxel (6), and
ortataxel (7) and their precursor 10-deacetylbaccatin III (8) isolated
from Taxus spp. (Taxus brevifolia in the Pacific Northwest, USA:
Courtesy of www.stevenfoster.com).

Fig. (3). Podophyllotoxin (9), a natural lignan isolated from
Podophyllum spp., and semi-synthetic anti-cancer drugs etoposide
(10), teniposide (11), and etoposide phosphate (12) (Podophyllum
peltatum in Texas, USA: by S.Y. Li).
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ceutical crops are being cultivated for possible antiviral
pharmaceuticals. For example, Syzygium claviflorum (Roxb.)
Wall. ex A.M. Cowan & Cowan (Myrtaceae), from Southeastern Asia and Australia, produces betulinic acid (22) (Fig.
8), a lupane triterpenoid used in the semi-synthesis of dimethyl succinyl betulinic acid (23) (Fig. 8) currently in antiAIDS clinical trials [24]. Lomatium suksdorfii J. M. Coult. &
Rose (Apiaceae), from the Pacific northwest of the United
States, is a major source of the anti-HIV (human immunodeficiency virus) coumarin suksdorfin (24) (Fig. 8), with semisynthetic analogs currently being tested in clinical trials.
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Fig. (4). Vinblastine (13) and vincristine (14), two natural vinca
alkaloids isolated from Catharanthus roseus, and semi-synthetic
anti-cancer drugs vinorelbine (navelvine) (15) and vindesine (eldisine) (16) (Catharanthus roseus, photo by M.J. Balick).

Active ingredients from several other pharmaceutical
crops are currently being evaluated in cancer drug clinical
trials, but severe side effects due to toxicity challenge drug
development. For example, Cephalotaxus Sieb. & Zucc.
(Cephaltaxaceae) native to southeastern Asia (including C.
fortunei Hooker, C. sinensis (Rehder & E. H. Wilson) Li, C.
oliveri Mast., C. mannii Hooker, and C. harringtonia
(Forbes) K. Koch.) are used to isolate the anti-tumor agents
harringtonine (17) and homoharringtonine (18) (Fig. 5), two
alkaloids used as cancer drugs in China [28]. Homoharringtonine (18) is being evaluated in clinical trials for treating
myeloid leukemia in the United States, but has severe side
effects [24]. Similarly, colchicine (19) isolated from
Colchicum autumnale L. (Liliaceae) (Fig. 6) is used to treat
gout and familial Mediterranean fever. The alkaloid and its
natural analog thiocolchicine (20) (Fig. 6) demonstrate
antileukemic activity by inhibiting the polymerization of
tubulin, but both are highly toxic [24].
Some pharmaceutical crops are managed for the production of other categories of drugs. Artemisia annua L., commonly known as wormwood or qinghao, is an annual herbaceous species native to China and now cultivated throughout
the world for production of the sesquiterpene lactone artemisinin (21) (Fig. 7) [7]. Artemisinin (21), used for semisynthesis of a common anti-malarial drug (Artemether), is
also under investigation for cancer treatment. Other pharmaO
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A number of pharmaceutical crops are being used to
produce APIs for recently approved drugs for other diseases,
such as Alzheimer’s, although some of the drugs are also
obtained synthetically. Galanthus woronowii Losinsk.
(Amaryllidaceae) and related genera, including Narcissus L.,
are sources of galantamine (Razadyne®/Razadyne® ER,
formerly known as Reminyl) (25) (Fig. 8) [29]. This alkaloid
is used for the treatment of mild to moderate Alzheimer’s
disease. The leaves of Callistemon citrinus Stapf. and the
seeds of Leptospermum scoparium Forst. & Forst. (two
shrubby species of the Myrtaceae from Australia and New
Zealand) are the major source of the allelopathic essential oil
leptospermone (26) (Fig. 8); its analog mesotrione (27) (Fig.
8) is used as a herbicide [30]. Recently, nitisinone (Orfadin®)
(28) (Fig. 8), a derivative of mesotrione, was the first drug
approved in Europe for the treatment of hereditary type 1
tyrosinemia, a rare genetic metabolic disorder caused by a
deficiency of the enzyme fumarylacetoacetate hydrolase
(FAH) encoded by the FAH gene. This enzyme is involved
in the metabolism of tyrosine [31].
Opium (Papaver somniferum L., Papaveraceae) is well
known as a natural source of important alkaloids such as
morphine (29) (a potent narcotic analgesic drug), thebaine
(30), codeine (31) (an analgesic antitussive drug), and
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Fig. (5). Harringtonine (17) and homoharringtonine (18), two natural alkaloids isolated from Cephalotaxus spp. (Cephalotaxus
harringtonia cultivated in Texas, USA, photo by S.Y. Li).

Fig. (6). Colchicine (19) and thiocolchicine (20), two natural alkaloids isolated from Colchicum autumnale (Colchicum autumnale,
photo by M.J. Balick).
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Fig. (7). Artemisinin (21) isolated from Artemisia annua (Artemisia
annua, photo by M.J. Balick).
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37

Fig. (10). Tropane alkaloids (−)-hyoscyamine (36) isolated from
Atropa belladonna and semi-synthetic tiotropium (37) (Atropa
belladonna, photo by M.J. Balick).

oripavine (32) (Fig. 9). Papaverine (33) (Fig. 9), another
opium poppy alkaloid, is a smooth muscle relaxant used
principally for the relief of cerebral and peripheral ischemia
associated with arterial spasm and myocardial ischemia
complicated by arrhythmias [32]. Apomorphine (34) (Fig. 9),
a semi-synthetic analog of morphine, was the first dopaminergic drug used to treat symptoms of Parkinson's disease
[33]. Recently, noscapine (35) (Fig. 9), another important
alkaloid found in opium poppy, has emerged as a promising
lead for chemoprevention and treatment of cancers especially
prostate cancer, and stroke [34]. Atropa belladonna L. (Fig.
10), Hyoscyamus niger L., and Datura stramonium L.
(Solanaceae) are sources of (−)-hyoscyamine (36) (Fig. 10)
and atropine ((±)-hyoscyamine) which are used as antimuscarinic agents. Anti-muscarinic alkaloids and synthetics
are used in the treatment of a number of digestive disorders.
They are also used to control excess motor activity of the
gastrointestinal tract and spasm of the urinary tract, to dilate
the pupils during ophthalmological examination of the eyes
and in cases of iritis, reduce respiratory secretions in
anesthesia, and nasal and sinus secretions in common cold
and allergy [32]. A semi-synthetic tropane analog, tiotropium
(37) (Fig. 10), is used for treatment of bronchospasms
associated with chronic obstructive pulmonary disease
(COPD) [35]. Scopolamine or hyoscine (38), another tropane
alkaloid found in Datura metel L. (Fig. 11), is used for
nausea and vomiting associated with motion sickness and for
preanesthetic sedation with analgesics [32]. Some other
important APIs are alkaloids ephedrine (39) (Fig. 12)
from Ephedra sinica Stapf (Ephedraceae), commonly known
as ephedra or Ma Huang, a potent sympathomimetic bronchodilator for bronchial asthma and local treatment of nasal
congestion [32, 36], physostigmine (40) (Fig. 12) used for
glaucoma and Alzheimer's disease from Physostigma venenosum Balf. (Calabar bean or ordeal bean; Fabaceae) [32,
37] and steroidal sapogenins diosgenin (41) (Fig. 12) from
Dioscorea spp. (yams; Dioscoreaceae) and hecogenin (42)
(Fig. 12) from Agava spp. (agaves; Agavaceae) for production of steroidal drugs [38, 39].
Other pharmaceutical crops produce inactive or less active pharmaceutical precursors used for synthesis of drugs.
Liquidambar styraciflua L., known as sweetgum (Hamamelidaceae), is one of the most common hardwood species
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Fig. (11). Scopolamine (38) isolated from Datura metel (Datura
metel, photo by R. Howard).

in the southeastern United States. Leaves of the tree contain
up to 13.4% shikimic acid (43) (Fig. 13) [40]. Shikimic acid
(43) has weak bioactivity, but is a precursor for the antiviral
drug Tamiflu®. Commercial harvest and extraction methods
for high concentrations of stable pure shikimic acid (43)
from the leaves have been developed [40], making L.
styraciflua a promising pharmaceutical crop.
Pharmaceutical Crops for the Production of Large
Therapeutic Molecules (LTMs)
Pharmaceutical crops for LTMs (usually having a molecular weight of more than 10,000 Daltons) include (1)
crops producing endogenous LTMs such as proteins and
polysaccharides, and (2) GM or engineered crops for producing exotic proteins such as vaccines and antibodies.
Plants produce a variety of bioactive proteins such as ribosome-inactivating proteins (RIPs), defensins, cyclotides,
and lectins [41]. Some of these proteins have shown promising anti-cancer, antiviral, and antifungal activities and improvement of immune function in humans [41, 42]. Some
important examples include antifungal and antiviral panaxagin from Asian ginseng (Panax ginseng C.A. Mey.; Araliaceae), quinqueginsin from North American P. quinquefolius
L., trichosanthin and TAP 29 from Trichosanthes kirilowii
Maxim. (Cucurbitaceae), Momordica Anti-HIV Protein
(MAP30) from Momordica charantia L. (Cucurbitaceae),
pokeweed antiviral protein (PAP) from leaves or seeds of

Fig. (13). Shikimic acid (43) isolated from Liquidambar styraciflua
(Liquidambar styraciflua in East Texas, USA, photos by S.Y. Li).

Phytolacca americana L. (Phytolaccaceae), saporin found in
seeds and leaves of Saponaria officinalis L. (Caryophyllaceae),
gelonin from the seeds of Gelonium multiflorum A. Juss.
(Euphorbiaceae), toxic ricin isolated from the castor bean
(Ricinus communis L.; Euphorbiaceae), viscumin from Viscum
album L. (Santalaceae), and abrin from seeds of Abrus
precatorius L. (Fabaceae) [41-46]. Some proteolytic enzymes
(proteases) isolated from plants are papain and chymopapain
isolated from latex of papaya (Carica papaya L., Caricaceae),
ficin from trunk latex of figs (Ficus carica L., F. glabrata
Kunth; Moraceae), and bromelain from stem and fruits of
pineapple (Ananas comosus (L.) Merr.; Bromeliaceae) [44].
Transgenic plants have been used for the production of
antibodies directed against dental caries, rheumatoid arthritis, cholera, E. coli diarrhea, malaria, certain cancers,
Norwalk virus, HIV, rhinovirus, influenza viruses, hepatitis
B virus, and herpes simplex virus [47]. Protein antigens from
various pathogens have been expressed in plants and used to
produce immune responses resulting in protection against
Vibrio cholerae, enterotoxigenic E. coli, hepatitis B virus,
Norwalk virus, rabies virus, human cytomegalovirus, rotavirus, and respiratory syncytial virus F [47]. In 2006, production of the monoclonal antibody CB-Hep.1 (used in the
manufacturing process for a Hepatitis B vaccine) in tobacco
plants was approved in Cuba [48]. GM pharmaceutical crops
could produce large quantities of drugs or vaccines at low
costs. Production of therapeutic proteins by transgenic pharmaceutical crops usually has shorter development cycles [5]
and lower cost than those from cell culture systems [47].
Like mammalian cells, plant production systems have the
advantage over microbial systems of being able to produce
active forms of complex proteins with appropriate posttranslational modifications (e.g., glycosylation) [47]. Additionally, using pharmaceutical crops reduces the risk for unintentional transformation of viruses that infect humans as
might occur when using mammalian cell systems.
Pharmaceutical Crops for the Production of Standardized Therapeutic Extracts (STEs)

Fig. (12). Ephedrine (39) isolated from Ephedra sinica, physostigmine (40) from Physostigma venenosum, diosgenin (41) from Dioscorea spp., and hecogenin (42) from Agava spp.

Crops in this category are usually used in traditional
medicine in various countries. It is estimated that several
thousand species are used for production of STEs in the
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world. Unlike STMs which are single molecular entities,
STEs are a mixture of multiple active compound(s) extracted
from pharmaceutical crops as standardized extracts. In this
case the crops may be wild harvested, sometimes managed in
local ecosystems, or cultivated in fields or environments
such as agroforests. STEs can be mixtures extracted from
one plant or from several to many different species. Many
STEs are marketed and utilized in the same fashion as drugs
in many parts of the world including China, Japan, India,
Europe, and Africa. In the United States, STEs are usually
classified as conventional foods and dietary supplements,
depending on the specific claim as described in the Dietary
Supplement Health and Education Act (DSHEA) of 1994.
There has been an increasing interest in further development
of STE drug products in recent years. In 2006, the FDA approved the first botanical drug Veregen® for the topical
treatment of patients with perianal and genital condyloma
[49]. The bioactivity of Veregen® is probably due to sinecatechins, a mixture of catechins found in the partially purified fraction of the water extract of green tea leaves from
Camellia sinensis (L.) Kuntze (Theaceae) (44-49) (Fig. 14),
as well as other green tea components.
Probably less than 1,000 species are cultivated, with most
of the species being harvested in the wild. With increasing
demands and decreasing resources in the wild, however,
more and more species are cultivated as crops for production
of STEs. Some well-known examples are Ginkgo biloba L.
(Ginkgoaceae), echinacea (Echinacea angustifolia DC., E.
purpurea (L.) Moench, E. palida (Nutt.) Nutt; Asteraceae),
liquorice (Glycyrrhiza glabra L.; Fabaceae), St. John's Wort
(Hypericum perforatum L.; Clusiaceae), ginseng (Panax
ginseng C.A. Meyer, Araliaceae), American ginseng (Panax
quinquefolius L., Araliaceae), pines (Pinus L., e.g., P. maritima Miller., P. sylvestris L., P. radiata D. Don, P. massoniana Lamb.; Pinaceae) (pine bark extract, containing proan-

thocyanidins), and Reishi (lingzhi) (Ganoderma tsugae,
Ganodermataceae).
STEs used as APIs could be a single class of active compounds or synergistic mixtures of several classes of bioactive
compounds. Cardiac glycosides such as oleandrin (50) and
digitoxin (51) (Fig. 15) are compounds known to inhibit
Na+/K+-ATPase activity and induce apoptosis [50, 51].
Members of this family of compounds have been in clinical
use for many years for the treatment of heart failure and
atrial arrhythmia [52]. Over the last ten years, emerging evidence has suggested that cardiac glycosides or cardiac glycoside containing botanical extracts have great potential for
managing malignant diseases [53-57]. For example, Anvirzel®, a hot water extract of oleander (Nerium oleander L.;
Apocynaceae) (Fig. 15) contains oleandrin (50) as a principle
cytotoxic component and has been evaluated in a Phase I
clinical trial in the United States against refractory human
cancers [50]. Additionally, the safety and anticancer response of the supercritical CO2 extract of oleander is currently being evaluated in a Phase I trial at The University of
Texas, M.D. Anderson Cancer Center. Ornamental oleander is
now cultivated as a pharmaceutical crop in the United States.
Some pharmaceutical crops are also cultivated for production of both STEs and STMs, i.e., Pueraria lobata
(Willd.) Ohwi (Fabaceae) for puerarin (52) (Fig. 16),
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Fig. (15). Cardiac glycosides such as oleandrin (50) from Nerium
oleander (photo by M.J. Balick) and digitoxin (51) from Digitalis
purpursea.
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Fig. (14). Catechins isolated from green tea leaves of Camellia
sinensis: (−)-epigallocatechin gallate (EGCG) (44), (−)-epicatechin
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Fig. (16). Puerarin (52) isolated from Pueraria lobata (Pueraria
lobata in Oxford, Mississippi, USA, photos by S.Y. Li).
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Lithospermum erythrorhizon Sieb. & Zucc. (Boraginaceae)
for shikinon (53) (Fig. 17), Salvia miltiorhiza Bunge (Lamiaceae) for tanshinone I (54), tanshinone IIA (55), salvianolic acid B (lithospermic acid B) (56), rosmarinic acid
(57), cryptotanshinone (58), and neotanshinlactone (59) (Fig.
18), and Glycyrrhiza glabra L. for glycyrrhizin (60) (Fig.
19). Salvia miltiorhiza, one of the most popular plants used
in traditional Chinese medicine, has been cultivated as a
pharmaceutical crop in many Asian countries for the treatment of coronary heart disease, cerebrovascular disease, and
inflammation [58, 59]. Although numerous varieties of S.
miltiorhiza have been grown since the 1960s, a high-yielding
cultivar is not yet available. The quality of APIs in cultivated
S. miltiorhiza is much lower than that in wild populations

[60]. Although the harvested biomass rhizome production
was increased significantly by applications of nitrogen fertilizers, the low and unstable yield of APIs has been a major
problem with this species [58]. The medicinal potential of
several other species of Salvia has been investigated [61, 62].
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Fig. (19). Glycyrrhizin (60) isolated from Glycyrrhiza glabra (photo
by M.J. Balick).

HOW PHARMACEUTICAL CROPS RELATE TO
OTHER PLANTS AND CROPS
Pharmaceutical crops are a class of crops incorporating
agriculture with medicine. Their relationships to medicinal
plants, crops, medicinal crops, and traditional food crops are
summarized in the Fig. 20.
Fig. (17). Shikinon (53) isolated from Lithospermum erythrorhizon
(photo by S.L. Chen).
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Fig. (18). Tanshinone I (54), tanshinone IIA (55), salvianolic acid
B (lithospermic acid B) (56), rosmarinic acid (57), cryptotanshinone (58), and neotanshinlactone (59) isolated from Salvia miltiorhiza (photo by Y.L. Lin).

Relationship to Medicinal Plants
There are over 70,000 plant species thought to be of medicinal value in the world [63]. Most of the medicinal plants
in the world are still harvested in the wild and have not been
developed as crops. In China, for example, there are approximately 31,000 plant species [64]. A total of 11,146
plant species have been recorded in Chinese herbal or medical literature according to a national survey conducted in
1995 [65]. Only 10% (1,200 species) are marketed as commercial medicines [66], of which 300 species are often cultivated as crops [58]. This trend is consistent with the use of
the angiosperms as food; while over 3,000 are known to be
used as foods only about 150 are in the economic system and

Pharmaceutical Crops: An Overview

of those only a handful are major crops with global nutritional significance.
Most of the natural products in clinical use today were
discovered through a routine examination of terrestrial plants
and microorganisms [67]. Most pharmaceutical crops have
their origins in previously known medicinal plants. However, some pharmaceutical crops emerged from the discovery, through established bioactivity-guided screens, of molecules in plants that have not previously been used in traditional medicine or considered as medicinal plants. Excellent
examples of this include taxanes from Taxus and CPT from
Camptotheca.
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market. Similarly, blueberries (Vaccinium L.; Ericaceae) are
mainly cultivated for their nutritious berries, but the leaves
are now also used for producing medicinal extracts [70].
Citrus fruits (Citrus L.,; Rutaceae) contain a variety of phytochemicals including flavonoids, limonoids, carotinoids,
and vitamin C, and serve as a source of folic acid, high quality soluble fiber, and potassium [71]. Recent identification of
the antiproliferative activity of limonoids (61) (Fig. 21) from
citrus against various human tumors [71-73] may lead to its
development as a pharmaceutical crop.

Relationship to Medicinal Crops
Many medicinal crops, originally cultivated for use in
traditional medicine are now managed as pharmaceutical
crops for STEs. For example, most of the 300 species commonly cultivated crops are currently also used for production
of STEs in addition to their traditional uses. Other medicinal
crops which are not used pharmaceutically, but which have a
long history in folk medicine (herbal preparations) are only
cultivated locally. These traditional medicinal crops could
have potential as pharmaceutical crops in the future. As discussed above, some medicinal crops such as Pueraria lobata, Lithospermum erythrorhizon, Salvia miltiorhiza, and
Glycyrrhiza glabra have been long cultivated as pharmaceutical crops for production of both STEs and STMs.
There is no clear definition for medicinal crops, the only
criterion being that this class of cultivated species has some
form of “traditional medicinal use”. However, not all pharmaceutical crops have medicinal uses. As mentioned above,
some food, vegetable, and spice crops are used for pharmaceutical purposes even though they are not typical medicinal
crops. Likewise, some pharmaceutical crops are used as
source of excipients (inert molecules) used in drug formulations as binders, fillers, disintegrants, emulsifying agents
(e.g., gum Arabic and gum tragacanth).
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Fig. (21). Limonoids (limonin (61)) isolated from citrus (Citrus)
(photos by S.Y. Li).

Celery (Apium graveolens L. var. dulce DC.; Apiaceae)
is an important vegetable crop. Apigenin (62) (Fig. 22), a
flavone isolated from celery which has been used to dye wool,
has been shown to possess remarkable anti-inflammatory,
antioxidant and anti-carcinogenic properties [74]. The cancer
chemo-preventive effects of apigenin (62) have recently been
reported [74].

Relationship to Traditional Food Crops
Some traditional food and vegetable crops are genetically
modified or engineered to produce therapeutic proteins and
thus are managed as pharmaceutical crops. In many cultures,
medicinal diets have a long history together with cereals,
vegetables, fruits, nuts, and spices which are used both as
food and medicine. Over 2,000 plant species have been used
as medicinal diets in China since the Tang Dynasty [68]. In
the last several decades, standardized extracts or pure isolates from some traditional food crops have been developed
as promising chemopreventive agents and even medicines
[68].
Some traditional food crops have been developed as nutritional crops which are defined as sources for extraction or
preparation of nutritional substances [69]. Nutritional crops
can be also considered as pharmaceutical crops when some
of their substances possess therapeutic properties. Grape
(Vitis L.; Vitaceae) is a common nutritional crop. A number
of studies suggest that grape seed extract (GSE, containing
antioxidant oligomeric proanthocyanidins or OPCs) is useful
for a variety of heart diseases and cancers. Many pharmaceutical products containing OPCs are available in the global
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Fig. (22). Apigenin (62) isolated from celery (Apium graveolens)
(photo by S.Y. Li).

Spice crops may also be cultivated as pharmaceutical
crops. Tumeric (Curcuma longa L.; Zingiberaceae) (Fig. 23)
and star anise (Illicium verum Hook. f.; Illiciaceae) are two
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Fig. (23). Curcuminoids (curcumin (63), demethoxycurcumin (64),
and bisdemethoxycurcumin (65)) isolated from tumeric (Curcuma
longa) (photos by S.Y. Li and M.J. Balick).

common spices in Asia, but they are also cultivated for production of the pharmaceutical ingredients curcuminoids and
shikimic acid (43), respectively. Curcuminoids, including
curcumin (63), demethoxycurcumin (64), and bisdemethoxycurcumin (65) (Fig. 23) have demonstrated antiinflammatory and anticancer activity and promising potential
in cancer prevention [75-77]. Aromatic plants not only serve
as condiments and as important resources in the perfume and
cosmetic industries, but have gained wide popularity now in
aromatherapy [78, 79].
Relationship to Invasive Species
Some well-known invasive species in the United States
such as kudzu or ge gen (Pueraria lobata), Japanese honeysuckle (Lonicera japonica Thunb.; Caprifoliaceae), and
Japanese climbing fern (Lygodium japonicum (Thunb.)
Sweet; Schizaeaceae) are currently managed as pharmaceutical crops in China and Japan. Kudzu is an invasive weed in
the southeastern United States (Fig. 16) which can completely replace existing vegetation. Eradication by herbicides
can cost over $200 per acre for five years and thus is often
commercially unfeasible [80]. In its native China, the vine is
managed as a pharmaceutical crop to prepare extracts or isolate puerarin (52), or as a food crop. Puerarin (52) can induce
angiogenesis in the myocardium and has been used to treat
patients with cardiovascular diseases [81].
Each year, 3 million acres of land in the United States are
taken over by invasive weeds. The spread of invasive plants
is ranked second, behind habitat loss, as the greatest threat to
biological diversity and ecosystem function in the United
States. Controlling invasive species and the associated economic and environmental damages amounts to more than
$138 billion per year [82]. More than $500 million is spent
on residential exotic weed control and an additional $1 billion is invested in non-indigenous weed control on golf
courses [82]. Efforts to control invasive species have been
focused on “negative actions” such as herbicide or mechanical applications or biological control. A focus on utilization
(positive actions such as identification of useful compounds
in existing invasive species and subsequent development of
these species as specialty or pharmaceutical crops valuable
enough to stimulate removal/harvest and utilization—not

Plants have formed the basis for traditional medicine systems which have been used for thousands of years in China,
India, and Egypt and later by the Greeks and Arabs. Botanical medicines still contribute to improving public health of
the majority of the world’s population [63, 83]. Plants have
also proven to be a major source for the discovery of modern
drugs, particularly in the cancer field [84]. Of 155 small
molecules developed as anti-cancer drugs worldwide from
the 1940s to the present time, 72.9% are naturally-inspired,
with 47% being either the natural products or semi-synthetic
derivatives [85]. Many well-known anti-cancer drugs are of
plant origin, e.g., CPTs (3-4), taxanes (5-7), podophyllins
(10-12), and vinca alkaloids (13-16) [67, 86]. Several experimental plant-based drugs have also shown promising
potential: homoharringtonine (18) (alkaloid from Cephalotaxus harringtonia) for leukemia; 4-ipomeanol (a pneumotoxic analog of furan isolated from Ipomoea batatas (L.)
Poir.) for lung cancer; elliptinium (a semi-synthetic analog
of ellipticine from Bleekeria vitiensis (Markgr.) A.C. Smith)
for advanced breast cancer; and flavopiridol (a synthetic flavone derived from alkaloid rohitukine isolated from Amoora
rohituka (Roxb.) Wight & Arn. and Dysoxylum binectariferum Hook. F. ex Bedd.) for colorectal cancer [87]. As Drs.
Wall and Wani stated, “undoubtedly, there are other highly
active natural products from plant, marine, and fungal
sources as yet unknown which, when discovered, will have
therapeutic utility. Cancer is not one, but several hundred
diseases and will require many different types of agents”
[18].
Plants are the obvious choice for future research of drug
development because they contain an almost infinite variety
of novel molecules [88]. Many compounds have very complex structures that are too difficult and expensive to
synthesize on an industrial scale. The global market for botanical and plant-derived drugs is expected to increase from
$19.5 billion in 2008 to $32.9 billion in 2013 [89]. However,
insufficient supply of source material has been one of the
major problems for bulk production of plant-based pharmaceuticals [90].
Pharmaceutical Crops as a Solution to Secure Sustainable Supplies of Quality Medicine
Of the world’s total flora of higher plants (estimated between 215,000 and 500,000 species), only 6% have been
screened for biological activity and 15% evaluated phytochemically [91, 92]. Actually, far fewer species have been
thoroughly screened or chemically investigated. Plants have
been proven and will continue to provide novel leads for
drug development [84, 90, 93-97]. Due to habitat destruction, overharvest, lack of sustainable utilization and conservation programs, however, species diversity and genetic diversity of medicinal plants are continuously under the threat
of extinction. It has been estimated that 22-46% of the
world’s total plant species are endangered [98].
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Many medicinal plants are being destroyed at an unprecedented rate and are threatened with extinction [63]. As
Balick and Mendelsohn pointed out, the value of sustainably
harvesting locally used medicinal plants in a forest plot in
Belize far exceeded the use of that same land for agriculture
[99]. The disappearance of medicinal plants, in addition to
reducing the access of a local population to primary health
care remedies, also threatens future efforts in drug discovery.
At present, of the 70,000 species of medicinal plants in the
world still primarily harvested in the wild, most have not
been cultivated as crops. For example, of the 3,000 species
of medicinal plants being traded in the world, 70-80% originate from wild-collections [100, 101], and only 900 have
commercial cultivation underway or in development [102].
Some 15,000 medicinal plant species may be threatened with
extinction [63].
Over-harvesting and loss of habitat often directly threaten
medicinal plants. Current supplies of many critical pharmaceuticals having global demands still rely on wild collection.
For example, Taxus tree species in North America and China
were harvested for bark and needles to produce the cancer
drugs paclitaxel (5) and docetaxel (6) and they are now in
endangered status. Cultivation of Taxus species has now
become essential to supplying these compounds. Hoodia
gordonii Sweet ex Decne (Asclepiadaceae) in Southern Africa and Namibia and some other species of the genus are
sources of weight loss drugs [103]. Hoodia gordonii is now
included in the Convention on the International Trade in
Endangered Species of Wild Fauna and Flora (CITES) Appendix II list in an attempt to control over-harvesting [103],
and again, cultivation of Hoodia is now underway.
Over 2,000 medicinal and aromatic plants are traded
commercially in Europe, and it is estimated that around 150
plant species are threatened in at least one European country
by this trade [104]. Colchicum autumnale L. (Colchicaceae)
used for gout is an example. Arnica montana Lam. (Asteraceae) and Gentiana lutea L. (Gentiaceae) are harvested
throughout Europe (especially in Bulgaria and Romania) but
are becoming scarce.
In China, of 354 species on the Chinese Endangered
Plant Species List, 168 species are medicinal plants [105].
Over 30 species often used in Chinese medicine are endangered and in short supply, e.g., ginseng, Glycyrrhiza glabra,
Angelica sinensis (Oliv.) Diels (Apiaceae), Ligusticum
chuanxiong S. H. Qiu, Y. Q. Zeng, K. Y. Pan, Y. C. Tang &
J.M. Xu (Apiaceae), Dysosma versipellis (Hance) M. Cheng
ex T. S. Ying (Berberidaceae), Changium smyrnioides H.
Woff (Apiaceae), Actinidia macrosperma C. F. Liang (Actinidiaceae), as well as three well-known woody medicinal
plants the bark of which is used namely, Magnolia officinalis
Rehder & E. H. Wilson (Magnoliaceae), Phellodendron
amurense Rupr. (Rutaceae), and Eucommia ulmoides Oliv.
(Eucommiaceae) [105, 106].
Extinction of wild plants will not only thwart the discovery of new drugs, but also limit the sustainable supply of
quality plant-based pharmaceuticals. In China, the decreasing genetic pool of wild plants has resulted in quality problems with products from over 100 species frequently used
for medicine [105]. Furthermore, indigenous knowledge of
the value of many medicinal plants is being lost very
quickly, although the vast majority of the earth’s plants have

Pharmaceutical Crops, 2010, Volume 1 11

yet to be thoroughly analyzed for their potential to improve
healthcare [103]. Ethnobotanical research has an important
role to play in drug discovery through establishing an inventory and then helping local people to conserve this aspect of
traditional knowledge [107-109].
Although the disappearance of many medicinal plants is
primarily the result of over-harvesting and loss of habitat, the
lack of sustainable agriculture systems and conservation
practices designed to maintain both biological and cultural
diversity threatens the future use of medicinal plants and
thus drug discovery programs. Current efforts such as in situ
and ex situ conservation strategies which include cultivation
in botanical gardens will preserve some endangered medicinal plant germplasm, but this should also include understanding and preservation of the knowledge of their value.
Development and cultivation of pharmaceutical crops, however, will not only conserve endangered medicinal biodiversity, but will also provide sustainable production of therapeutic molecules. In addition, pharmaceutical crop research
will help to conserve and utilize decreasing biological and
cultural diversity and thus enhance the potential for drug
discovery.
Development of pharmaceutical crops will secure supplies of vital medicines particularly important in emergent
cases such as threat of pandemic infectious diseases. Some
countries must currently import APIs to produce antiviral
and anti-cancer drugs, and foreign supplies may be uncertain. Cultivation of newly emerging pharmaceutical crops in
these locations may open the door to less expensive and
more readily available drugs, and revitalize rural economies
by establishing high-value crops.
Problems and Challenges with Pharmaceutical Crop Development
At present, when compared to research and development
of food and fiber crops, similar programs to address pharmaceutical crops for therapeutic are very limited. Unlike traditional food crops and yet-to-be-developed energy crops for
biomass, research in pharmaceutical crops focuses on the
maximization and sustainable production of target chemical
compound(s) from the plants. This involves the integration
of techniques used in traditional crops including plant breeding, physiology and ecology, coupled with research in the
fields of pharmacognosy, pharmacology, and eventually
clinical studies. Integration of these different areas with interdisciplinary teams of scientists working towards a common goal appears to be the key to success.
The discoveries of CPT (1) and Taxol® (5) by Drs. Wall
and Wani “firmly established the fact that the close cooperation between chemists and botanists was required for a successful natural products program” [18]. In search of novel
bioactive natural products, chemists commonly start with
dried plant parts (or tissues) provided by botanists and may
never see the living plants. In contrast, botanists and plant
physiologists are primarily focused on the content variations
or biosynthesis of target compounds in intact plants or cell
culture systems. Both chemists and biologists realize that
inducible biosynthesis of target compounds will require extensive efforts in in vitro production and microbial biotransformation of these compounds. However, management of
intact plant systems as reactors for derivatization of novel

12 Pharmaceutical Crops, 2010, Volume 1

Li et al.

O
N
Camptotheca acuminata

N
O

Broken glandular
trichome

CPT

OH O
Untreated glandular
trichome
10 µm

10 µm
5 mm

Fig. (24). “Trichome Management” method to induce biosynthesis and derivatization of camptothecin (CPT) in Camptotheca acuminata:
glandular trichomes on the leaf and stem surfaces as accumulation sites of CPTs are management target in selection and cultivation of highyielding variety [14, 16, 103] (photos by S.Y. Li and K. Northrup).

bioactive agents has never been seriously addressed. As a
matter of fact, important secondary metabolites such as morphine are produced in significant amounts only in the intact
plant, with the biosynthetic pathway being repressed in cell
culture. Pharmaceutical crops are platforms for biologists,
chemists, pharmacists, health professionals and clinicians to
collaborate closely in making new drug discoveries in all
disease areas. Several problems have tempered both industrial and academic enthusiasm for research and funding in
pharmaceutical crops as a production system, particularly for
the production of STMs in great global demand. In addition
to decreasing genetic diversity in nature and environmental
concerns (i.e., endangered species), factors including slow
plant growth, long harvest cycle, and low and unstable yields
of desired compounds in wild plants have been major problems in the large scale management of crops and production
of the pharmaceuticals. Often, the yield and quality of pharmaceuticals from cultivated plants is not equivalent to those
in the wild, even in common crops with a long cultivation
history, such as Salvia miltiorhiza [58, 60]. Therefore, priority research in both intact plant and cell culture (when feasible) should be carried out to select and develop high and
stable yielding varieties or strains having the desired target
compound(s).
Future pharmaceutical crop research efforts should also
emphasize the strategies to enhance the yield of therapeutic
molecules or precursors in sustainable crop production systems. To obtain a diversity of bioactive analogs, methods
need to be developed to increase derivatization of the desired
compounds in intact plants or in vitro systems, in addition to
exploring microbial biotransformation. In some cases, STMs
or precursors accumulate in glandular trichomes of plants.
The shape and size of glandular trichomes from different
species within a genus may vary considerably but are highly
heritable [14, 16]. Induction of the production of glandular
trichome in plants could significantly increase the yield of
the target compounds. In the 1990s, the “Trichome Management” technique was developed to increase both biomass

of leaves and stems and the density of glandular trichomes
on leaves and stems by controlling auxin levels [14, 16] (Fig.
23 to Fig. 24). This method induced production of glandular
trichomes and thus increased alkaloid CPT yield by 16 to 20fold, and derivatization of CPT in Camptotheca [14, 16, 110,
111]. The alkaloidal induction by auxin reduction in Camptotheca consists of two steps: an emergent response to translocate alkaloids from old to young tissues and a systematic
response to increase alkaloidal contents in the entire plant
[16]. Recently, trichome density was used as a trait to
quickly screen and develop high-yielding varieties of Artemisia annua for sesquiterpenoid artemisinin yield [112]. Although both trichome density and secondary metabolites
may be inducible by auxin-reducing pruning [16, 40, 110],
the induction mechanism remains elusive. Existing hypotheses attempting to explain the increase in secondary metabolite concentration after damage are conflicting (supply-side
vs. demand-side); but both emphasize the defense function
of secondary metabolites, particularly of phytoalexins [113,
114]. However, the role of defense in induced biosynthesis
of toxic compounds in plants needs further investigations.
The chemicals produced by Taxus spp., Artemisia annua,
and Camptotheca spp. are among the most extensively investigated. There is no information on whether protection
from herbivores or pathogens occurs in Taxus or Artemisia
[115]. In Camptotheca, elevated toxic CPTs did not increase
the antifungal activity of the plants but actually induced
plant endogenous autotoxicity [110]. Thus, a chemical defense role should not be overemphasized in the induced biosynthesis of some toxic secondary metabolites. Another interesting topic worthy of investigation is the cyclical nature
of plant chemical levels within individuals of the same species. For example, in Hypericum perforatum, levels of hypericin and pseudohypericin were found to vary between 100
ppm and 5,000 ppm from winter to summer [116].
Selection of optimum or suitable zones for crop cultivation is important to the development of high-yield and sustainable production systems, particularly for crops with long
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harvest cycles. The process involves analysis of multiple
factors in ecology, climatology, geology, biology, and chemistry. Recently, some GIS (Geographic Information System)based models for adaptability analysis were established
[117]. Some regional zoning efforts have also been made
with several common traditional medicinal crops in China
[117]. In non-native ranges, conducting field trials over large
regions are time and cost prohibitive and could limit cultivation of crops in new areas.
The difficulty in isolating and characterizing complex
natural products is becoming less of a problem as HPLC-MS
and HPLC-NMR are more routinely used and new methods
for isolation and structural elucidation continue to be developed [90]. However, purification of some desired compounds from pharmaceutical crops, and particularly the
elimination or reduction of interfering compounds in plants
continues to be a major challenge in extraction. Effective
isolation of desired compounds in intact plant systems needs
to be further investigated.
In recent decades there have been great efforts and significant progress in exploring other options to produce therapeutic compounds. Although chemical synthesis is a commercially feasible option for those compounds with relatively simple structures such as aspirin and ephedrine, it is
not an appropriate strategy for complex structures [118-120].
Semi-synthesis from more abundant natural precursors is
often necessary to prepare structurally complex drugs, e.g.,
semi-synthesis of taxane-based drugs (5-7) from natural baccatins isolated from Taxus spp. [22, 23]; also semi-synthesis
is often used to convert toxic natural products to derivatives
having more acceptable pharmacological properties, e.g., the
conversion of CPT (1) to topotecan (3) and irinotecan (4).
Metabolic engineering of target secondary metabolites in
plants is feasible, but requires knowledge of the biosynthetic
pathways [121]. The secondary metabolic pathways of only
a few plants have been studied in detail which limits progress in this area [119, 121]. Catharanthus roseus and Rauvolfia serpentina Benth. ex Kurz (Apocynaceae) have been
used as model systems for the investigation of monoterpene
indole alkaloid production by in vitro culture techniques,
particularly cell suspension cultures, since the early 1980s
[119]. However, C. roseus and R. serpentina crops are still
the only viable commercial source of the anti-cancer vinca
alkaloids and anti-hypertensive Rauwolfia alkaloids [119,
122, 123]. Successful examples of secondary metabolite
production by plant cell suspension cultures include the anticancer paclitaxel (5) from Taxus spp.; the anti-cholinergic
scopolamine (38) from Duboisia spp. (Solanaceae); the antibiotic berberine from Coptis japonica Makino (Ranunculaceae); the anti-inflammatory rosmarinic acid (57) from
Coleus blumei Benth. (Lamiaceae); and the anti-inflammatory
and antiviral shikonin (53) from Lithospermum erythrorhizon
Siebold et Zucc. (Boraginaceae) [124]. Other options including expression of plant pathways in microbial systems have
been explored. The commercial potential of hairy root cultures for production of plant-derived pharmaceuticals has
been limited primarily due to challenges in cultivating hairy
roots in a large scale system [120]. Research and development in these fields will definitely enhance the pivotal role
of pharmaceutical crops. In general, however, the use of intact plant systems means lower cost of production and easier
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expansion for large-volume production [47]. Instead of a
large capital investment in cell culture facilities, plant production systems can be expanded simply by growing and
harvesting additional plants.
Conservation biologists and ecologists have raised concerns about the biosafety and environmental impacts of GM
pharmaceutical crops. The potential environmental impacts
(e.g., gene flow between cultivated crops and their wild relatives) of genetically engineered crops for pharmaceuticals
need constant analysis and evaluation. However, the use of
biotechnology in pharmaceutical crops and conservation of
biodiversity are not mutually exclusive.
Another issue is reciprocity to indigenous cultures and
people that contributed knowledge and resources for development of pharmaceutical crops and their products. To ensure that more equitable benefits accrue from the use of biological resources, the United Nations Convention on Biological Diversity (CBD) was drafted during the Earth Summit in Rio de Janiero in 1992 [125]. Since then, there has
been an increasing awareness in developing countries of the
potential value of their indigenous genetic resources [126].
In fact, governments and conservation biologists have made
extensive efforts to ensure the sustainable use of biodiversity
and benefit sharing from revenues generated from plants
originally used by indigenous and local people in traditional
medicine. Shaman Pharmaceuticals developed a model for
the pharmaceutical industry to have multi-stage benefit sharing with governments and traditional cultures in its drug discovery from Amazonian plants [125, 127], and the National
Cancer Institute produced a series of agreements to address
this issue that are also used as models by others [126]. Recently, some have argued that all nature-based patents should
acknowledge evolution by natural selection as a ‘coinventor’ and should allocate 1% of patent ownership towards efforts to conserve biodiversity [128].
CONCLUSIONS
Pharmaceutical crops can be defined as cultivated species
that are used for the extraction or preparation of therapeutic
substances such as active pharmaceutical ingredients (APIs),
excipients used in pharmaceutical formulations, vaccines and
antibodies, as well as other therapeutic proteins. Basically,
there are three types of pharmaceutical crops: crops for the
production of small therapeutic molecules (STMs), large
therapeutic molecules (LTMs), and standardized therapeutic
extracts (STEs). This review focuses on examples of terrestrial plants although pharmaceutical crops could be either
terrestrial or aquatic species. Pharmaceutical crops are a relatively new class of crops having close relationships with
medicinal plants, medicinal crops, and traditional crops. Unlike traditional food crops and yet-to-be-developed energy
crops for production of biomass, research in pharmaceutical
crops focuses on the maximization and sustainable production of target chemical compound(s) from the plants. This
involves the integration of techniques used in traditional
crops including plant breeding, physiology and ecology,
coupled with research in the fields of pharmacognosy, pharmacology, and eventually clinical studies. Successful development of pharmaceutical crops requires extensive joint efforts of scientists in these different fields. Research in the
area of invasive species has been focused on elimination, but
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the potential for the development of some species as pharmaceutical crops needs to be exploited. Future development
of pharmaceutical crops should emphasize strategies to enhance the yield and derivatization of therapeutic molecules
or precursors in sustainable crop production systems, including development of high-yielding cultivars, cultivation technology for induced production of desired compounds, and
effective and environmental-friendly extraction methods. In
addition, biosafety, environmental impacts, and benefit sharing should be addressed in the research and development of
pharmaceutical crops.
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